The impact of the prohibition of benzylpiperazine (BZP) 'legal highs' on the prevalence of BZP, new legal highs and other drug use in New Zealand

Drug and Alcohol Dependence

Volumn 127, Issue 1-3, 2013, Pages 72-80

  Wilkins, Chris ^a   Sweetsur, Paul ^a  

^a MASSEY UNIVERSITY   (New Zealand)

Author keywords

Benzylpiperazine (BZP); Frequent drug users; General population; Legal highs; Prohibition

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; BENZYLPIPERAZINE; COCAINE; METHAMPHETAMINE; METHYLPHENIDATE; NITROUS OXIDE; PIPERAZINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ALCOHOL ABUSE; ARTICLE; DRUG ABUSE; DRUG ABUSE PATTERN; DRUG CONTROL; DRUG LEGISLATION; DRUG TRAFFIC; HEALTH SURVEY; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; NEW ZEALAND; PRIORITY JOURNAL; SUBSTANCE ABUSE;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PIPERAZINES; POPULATION SURVEILLANCE; PREVALENCE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 84870873030     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2012.06.014     Document Type: Article

References (67)

1. Antia U., Lee H.S., Kydd R.R., Tingle M.D., Russell B.R. Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci. Int. 2009, 186:63-67.
2. Babor T., Caulkins J., Edwards G., Fischer B., Foxcroft D., Humphreys K., Obot I.S., Rehm J., Reuter P., Room R., Rossow I., Strang J. Drug Policy and the Public Good 2010, Oxford University Press, Oxford.
3. Bachman J., Johnston L., O'Malley P. Explaining the recent decline in cocaine use among adults: further evidence that perceived risks and disapproval lead to reduced drug use. J. Health Soc. Behav. 1990, 31:173-184.
4. Balmelli C., Kupferschmidt H., Rentsch K., Schneemann M. Fatal brain edema after ingestion of ecstasy and benzylpiperazine (German). Dtsch. Med. Wochenschr. 2001, 126:809-811.
5. Baumann M., Clark R., Budzynski A., Partilla J., Blough B., Rothman K. Effects of "Legal X" piperazine analogs on dopamine and serotonin release in rat brain. Ann. N.Y. Acad. Sci. 2004, 1025:189-197.
6. Baumann M., Clark R., Budzynski A., Partilla J., Blough B., Rothman R. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 2005, 30:550-560.
7. Bewley-Taylor D., Hallam C., Allen R. The Incarceration of Drug Offenders: an Overview. (Report Sixteen) 2009, Beckley Foundation Drug Policy Programme, Oxford.
8. Brown B., Gauvey S., Meyers M., Stark S. In their own words: addicts' reasons for initiating and withdrawing from heroin. Int. J. Addict. 1971, 6:639-642.
9. Bye C., Munro-Faure A., Peck A., Young P. A comparison of the effects of l-benzylpiperazine on human performance tests. Eur. J. Clin. Pharmacol. 1973, 6:163-169.
10. Campbell H., Cline W., Evans M., Lloyd J., Peck A. Comparison of the effects of dexamethamphetamine and l-benzylpiperazine in former addicts. Eur. J. Clin. Pharmacol. 1973, 6:170-176.
11. Cohen B., Butler R. BZP-party pills: a review of research on benzylpiperazine as a recreational drug. Int. J. Drug Policy 2011, 22:95-101.
12. Dawkins K. The great BZP hoax. N.Z. Law J. 2008, (July):250-253.
13. European Monitoring Centre for Drugs and Drug Addiction, 2007. Risk Assessment report of a new psychoactive substance: 1-benzylpiperazine (BZP). (In accordance with Article 6 of Council Decision 2005/387/JHA on information exchange, risk assessment and control of new psychoactive substances), Lisbon.
14. European Monitoring Centre for Drugs and Drug Addiction, 2008. Council Decision: 'Appropriate Controls' for BZP - New Drug BZP to be Placed Under Control Across the EU (News Release No. 2/2008), Lisbon.
15. European Monitoring Centre for Drugs and Drug Addiction New drugs and emerging trends. Annual Report 2010: The State of the Drugs Problem in Europe 2010, EMCDDA, Lisbon.
16. European Monitoring Centre for Drugs and Drug Addiction, 2011a. First international multidisciplinary forum on new drugs, 11-12 May 2011, Lisbon. Concluding remarks [EMCDDA]. Retrieved 31 August 2011. Available from: http://www.emcdda.europa.eu/news/2011/new-drugs-forum-conclusion.
17. European Monitoring Centre for Drugs and Drug Addiction New drugs and emerging trends. Annual Report 2011: the State of the Drugs Problem in Europe 2011, Publications Office of the European Union, Luxembourg, pp. 93-100.
18. Expert Advisory Committee on Drugs Further EACD Advice on Benzylpiperazine (BZP) and Related Substances 2006, EACD, Wellington.
19. Fendrich M., Johnson T., Wislar J., Hubbell A., Spiehler V. The utility of drug testing in epidemiological research: results from a general population survey. Addiction 2004, 99:197-208.
20. Gee P., Fountain J. Party on? BZP party pills in New Zealand. N.Z. Med. J. 2007, 120:U2422.
21. Gee P., Richardson S., Woltersdorf W., Moore G. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N.Z. Med. J. 2005, 118:U1784.
22. Green J. Partying on? Life after BZP-based party pills. N.Z. Med. J. 2008, 121:35-42. http://journal.nzma.org.nz/journal/121-1283/3289/.
23. Griffiths P., Sedefov R., Gallegos A., Lopez D. How globalization and market innovation challenge how we think about and respond to drug use: 'spice' case study. Addiction 2010, 105:951-953.
24. Hall W., Degenhardt G., Lynskey M. The Health and Psychological Effects of Cannabis Use. (Monograph Series No. 44) 2001, Commonwealth Department of Human Services and Health, Canberra.
25. Hammersley R. Dangers of banning spice and the synthetic cannabinoid agonists. Addiction 2010, 105:373.
26. Harding J., Huckle T., You R.Q. Feasibility of random digit dial cell phone sampling and the effect of cell phone only respondents on population estimates. Field Method 2011, submitted for publication 1 April 2011.
27. Harrison L., Martin B., Enev T., Harrington D. Comparing Drug Testing and Self-report of Drug Use Among Youths and Young Adults in the General Population 2007, Office of Applied Studies, Substance Abuse and Mental Health Services, US Department of Health and Human Services, Washington, DC, Retrieved 31 August 2011. Available from: http://www.oas.samhsa.gov/validity/drugTest.pdf.
28. Hillebrand J., Olszewski D., Sedefov R. Legal highs on the internet. Subst. Use Misuse 2010, 45:330-340.
29. Kandel D., Chen K., Warner L., Kessler R., Grant B. Prevalence and demographic correlates of symptoms of last year dependence on alcohol, nicotine, marijuana and cocaine in the U.S. population. Drug Alcohol Depend. 1997, 44:11-29.
30. Kleiman M. Against Excess: Drug Policy for Results 1992, Basic Books, New York.
31. Lin J.C., Bangs N., Lee H., Kydd R.R., Russell B.R. Determining the subjective and physiological effects of BZP on human females. Psychopharmacology 2009, 207:439-446.
32. MacCoun R. Drugs and the law: a psychological analysis of drug prohibition. Psychol. Bull. 1993, 113:497-512.
33. MacCoun R. Estimation of the Non-Price Effects of Legalization on Cannabis Consumption 2010, RAND, Santa Monica, CA.
34. MacCoun R., Reuter P. Drug War Heresies: Learning from Other Vices, Times, and Places 2001, Cambridge University Press, New York.
35. Marre, O., 2008. The right stuff? The Guardian, 16 November. Retrieved from http://www.guardian.co.uk/society/2008/nov/16/drugs-legal-highs-confusing.
36. McAuliffe W., Geller S., La Brie R., Paletz S., Fournier E. Are telephone surveys suitable for studying substance abuse? Cost, administration, coverage and response rate issues. J. Drug Issues 1998, 28:455-482.
37. McElrath K., O'Neill C. Experiences with mephedrone pre- and post-legislative controls: perceptions of safety and sources of supply. Int. J. Drug Policy 2011, 22:120-127.
38. Measham F., Moore K., Newcombe R., Welch Z. Tweaking, bombing, dabbing and stockpiling: the emergence of mephedrone and the perversity of prohibition. Drug Alcohol Today 2010, 10:14-20.
39. Moore M. Drugs: getting a fix on the problem and the solution. Yale Law Policy Rev. 1990, 8:701-728.
40. Musto D.F. The American Disease 1987, Yale University Press, New Haven, CT.
41. New Zealand Law Commission, 2011. Controlling and Regulating Drugs - a Review of the Misuse of Drugs Act 1975, Wellington.
42. Nicholson T. Prevalence of use, epidemiology and toxicity of 'herbal party pills' among those presenting to the emergency department. Emerg. Med. Australas. 2006, 18:180-184.
43. Poon W., Lai C., Lui M., Chan A., Mak T. Piperazines: a new class of drug abuse has landed in Hong Kong. Hong Kong Med. J. 2010, 16:75.
44. Reuter P., Kleiman M. Risks and prices: an economic analysis of drug enforcement. Crime and Justice: an Annual Review of Research 1986, 289-340. University of Chicago Press, Chicago. M. Tonry, N. Morris (Eds.).
45. Schelling T. Addictive drugs: the cigarette experience. Science 1992, 255:430-433.
46. Sheridan, J., Butler, R., 2006. Legal party pills and their use by young people in New Zealand: a qualitative study, final report on findings. School of pharmacy, University of Auckland, Auckland.
47. Sheridan J., Butler R. They're so legal they're safe, right? What did the legal status of BZP-party pills mean to young people in New Zealand?. Int. J. Drug Policy 2009, http://dx.doi.org/10.1016/j.drugpo.2009.1002.1002.
48. Sheridan J., Butler R., Wilkins C., Russell B. Legal piperazine-containing party pills - a new trend in substance misuse. Drug Alcohol Rev. 2007, 26:335-343.
49. Social Tonics Association of New Zealand Submission of Social Tonics Association of New Zealand to the Health Select Committee on the matter of Misuse of Drugs Amendment Bill (No. 3) and the Supplementary Order Paper 2005, Social Tonics Association of New Zealand, Auckland.
50. Staack R. Piperazine designer drugs of abuse. Lancet 2007, 369:1411-1413.
51. Theron L., Jansen K., Miles J. 'Benzylpiperizine-based party pills' impact on the Auckland City Hospital Emergency Department Overdose Database (2002-2004) compared with ecstasy (MDMA or methylene dioxymethamphetamine), gamma hydroxybutyrate (GHB), amphetamines, cocaine, and alcohol. N.Z. Med. J. 2007, 120. http://www.nzma.org.nz/journal/120-1249/2416/.
52. TVNZ, 2007. Blackmarket concerns for party pills. Retrieved 29 June. Available from: http://tvnz.co.nz/view/page/411749/1206863.
53. United Nations Office on Drugs and Crime, 2011a. Overview of global and regional drug trends and patterns, World Drug Report 2011, UNODC, Vienna.
54. United Nations Office on Drugs and Crime Synthetic cannabinoids in herbal products 2011, UNODC, Vienna.
55. Vince G. Legally high. New Sci. 2006, 191(2571):40-45.
56. Weatherburn D., Jones C., Donnelly N. Prohibition and cannabis use in Australia: a survey of 18- to 29-year olds. Aust. N.Z. J. Criminol. 2003, 36:77-93.
57. Wilkins C., Casswell S., Moewaka-Barnes M., Pledger M. A pilot of a computer assisted cell-phone interview (CACI) methodology to survey respondents in households without telephones about alcohol use. Drug Alcohol Rev. 2003, 22:221-225.
58. Wilkins C., Girling M., Sweetsur P. The prevalence of use, dependency and harms of legal 'party pills' containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand. J. Subst. Use 2007, 12:213-225.
59. Wilkins C., Girling M., Sweetsur P., Huckle T., Huakau J. Legal Party Pill use in New Zealand: Prevalence of Use, Availability, Health Harms and 'Gateway Effects' of Benzylpiperazine (BZP) and Triflourophenylmethylpiperazine (TFMPP) 2006, Centre for Social and Health Outcomes Research and Evaluation (SHORE) & Te Ropu Whariki, Massey University, Auckland.
60. Wilkins C., Sweetsur P. Trends in population drug use in New Zealand: findings from national household surveying of drug use in 1998, 2001, 2003 and 2006. N.Z. Med. J. 2008, 121:61-71.
61. Wilkins C., Sweetsur P., Girling M. Patterns of benzylpiperazine/trifluoromethylphenylpiperazine (BZP/TFMPP) party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev. 2008, 27:633-639.
62. Wilkins C., Sweetsur P., Huckle T., Asiasiga L., Griffiths R. The impact of the prohibition of benzylpiperazine (BZP) on the use and harm of BZP in New Zealand 2009, Centre for Social and Health Outcomes Research and Evaluation (SHORE) & Te Ropu Whariki, Massey University, Auckland.
63. Wilkins C., Sweetsur P., Griffiths R. Recent trends in pharmaceutical drug use among frequent injecting drug users, frequent methamphetamine users and frequent ecstasy users in New Zealand, 2006-2009. Drug Alcohol Rev. 2011, 30:255-263.
64. Wilkins C., Sweetsur P., Smart B., Griffiths R. Recent Trends in Illegal Drug Use in New Zealand, 2006-2010: Findings from the 2006, 2007, 2008, 2009 and 2010 Illicit Drug Monitoring System (IDMS). Social and Health Outcomes Research and Evaluation (SHORE) 2011, Massey University.
65. Winstock A. Mepedrone: still available and twice the price. Lancet 2010, 376:1537.
66. Winstock A., Mitcheson L., Ramsey J. Legal highs and the challenges for policy makers. Addiction 2010, 105:1685-1687.
67. Winstock A., Wilkins C. 'Legal highs' the Challenge of New Psychoactive Substances. (Series on Legislative Reform of Drug Policies Nr. 16) 2011, Transnational Institute (TNI), Amsterdam.